Using the Flory−Huggins parameter and a previously measured value of the Maier−Saupe parameter, the PPV-b-PI phase diagram may be converted from system-specific variables to dimensionless parameters.

The ionic partition diagram methodology has been generalized to address both hydrophilic and lipophilic compounds and to consider biphasic systems with variable phase volume ratios. With this ...

Phase-change materials are some of the most promising materials for data-storage applications. They are already used in rewriteable optical data storage and offer great potential as an emerging ...

President Donald Trump said Tuesday that he plans to phase out the Federal Emergency Management Agency after this year’s hurricane season, offering the clearest timeline yet for his ...

High-capacity wireless links at millimeter-Waves are candidate for backhaul infrastructure to small-cell mobile networks. However, the use of high-order modulation schemes sets challenging phase-noise ...

Citing Maui’s severe post-wildfire housing crisis, the Bissen administration presented its formal case to a County Council committee to phase out approximately 6,000 short-term vacation rentals ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

Methods: NIVOPOSTOP is an international randomized, open-label Phase 3 trial (NCT03576417). Main inclusion criteria were patients < 75 years, ECOG PS 0-1, with resected LA-SCCHN of the oral cavity, ...

Southern California’s air quality regulators are set to vote this week on new rules aimed at phasing out the sale of gas-powered furnaces and water heaters in the region.

Moonlake is running phase 3 studies of the nanobody in psoriatic arthritis and advancing the drug candidate toward pivotal trials in psoriasis, palmoplantar pustulosis and axial spondyloarthritis.

The KT-621 Phase Ib trial in moderate and severe AD is actively recruiting with data expected in Q4 of 2025. Additionally, two parallel Phase IIb trials in AD and asthma are planned to start in Q4 ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...